Dutch Startup Investments Stagnate in Early 2025

2025-04-09 community

Amsterdam, Wednesday, 9 April 2025.
Q1 2025 shows significant stagnation in Dutch startup investments, raising €460 million, with noticeable declines in sectors like biotech, despite standout investments from Leyden Labs and Alesta Therapeutics.

Investment Landscape Overview

The Dutch startup ecosystem has experienced a notable decline in investment activity during the first quarter of 2025, with total investments reaching €460 million [1]. This stagnation becomes particularly evident when examining the country’s position in European rankings, where the Netherlands has dropped three places to seventh position [1]. The slowdown is occurring against a backdrop of robust global venture funding, which reached $113 billion in Q1 2025, marking a 17 percent increase from Q4 2024 [3].

Sector-Specific Performance

The biotech sector has been particularly affected, with investments dropping by 59% compared to Q1 2024 [1]. However, amid this general downturn, several companies have secured significant funding rounds. Notably, Leyden Labs and Alesta Therapeutics raised €70 million and €65 million respectively [1][5]. In the healthtech domain, Dutch companies have shown resilience, with the sector raising $177 million (approximately €161.73 million) across 10 rounds in early 2025 [5].

Market Dynamics and Challenges

The investment landscape shows concerning trends in deal volume, with the number of transactions decreasing from 89 to 79, while larger investment rounds exceeding €15 million have seen a significant reduction [1]. Industry leaders express growing concern about this trajectory. According to Lucien Burm of the Dutch Startup Association, ‘To stand still is to go backwards,’ highlighting the urgent need for proactive measures to improve the investment climate [1]. This slowdown is particularly noteworthy given that U.S. startups have raised a record $80 billion in the same quarter [3].

Future Outlook and Opportunities

Despite current challenges, certain sectors continue to show promise. The healthtech segment demonstrates particular resilience, with companies like VarmX securing €15 million in follow-on equity investment [5]. However, industry experts emphasize the need for strategic intervention. Leading venture capitalists, including Dagmar van Ravenswaay Claasen from LUMO Labs, are advocating for more diverse teams and impact-driven investments in health and sustainability sectors [6]. The market’s recovery may depend on implementing these structural changes and adapting to evolving investment patterns.

Bronnen

investment startup